Comparing the Efficacy and Daily Burdens of Atropine, Ortho-K, and Multifocal Lenses for Pediatric Myopia

The outcome of pediatric myopia is not determined when a child first squints at a whiteboard, but during the narrow developmental window when the eyeball itself is actively elongating. This structural stretching—known clinically as axial elongation—is the step that permanently dictates a child's lifelong risk for retinal detachment, glaucoma, and myopic maculopathy. Because an elongated eye cannot be shrunk, the only effective intervention is to interrupt the growth signal before the sclera permanently remodels.[6]

For generations, the standard response to a child's worsening vision was simply to prescribe thicker single-vision glasses. However, standard lenses only move the focal point to correct the blur; they do nothing to stop the eye from continuing to grow. Today, clinical consensus has shifted entirely toward active myopia management, utilizing therapies that alter the optical signals reaching the peripheral retina or chemically relax the eye's focusing mechanisms.[2][6]

Parents navigating this landscape are generally presented with three primary, evidence-based options: low-dose atropine eye drops, orthokeratology (Ortho-K) overnight lenses, and daytime multifocal soft contact lenses. While the mechanisms differ wildly—ranging from pharmacological receptor blocking to physical corneal reshaping—the clinical targets are identical. The goal is to reduce the rate of axial elongation by roughly 50% compared to children wearing standard glasses.[4][6]

The challenge for families is that no single treatment is universally superior. A 2024 meta-analysis of Ortho-K wearers found that while the lenses provided a statistically significant reduction in axial elongation of 0.24 millimeters over two years, approximately 25% of children showed no benefit from the treatment. Conversely, about 40% experienced remarkably low levels of progression, demonstrating that individual response varies heavily.[4]

Pharmacological approaches show similar nuance. The landmark LAMP (Low-Concentration Atropine for Myopia Progression) study revealed a clear dose-dependent response. While 0.01% atropine was long considered the standard, recent data indicates that a 0.05% concentration is significantly more effective at reducing axial elongation over two years, particularly in younger children. However, a 2026 meta-analysis of 1,091 children using the lower 0.01% dose found it yielded only modest reductions of 0.05 millimeters per year in axial length, highlighting the importance of proper dosing.[1][3]

Soft multifocal lenses offer a third path. In 2019, the U.S. Food and Drug Administration approved the MiSight 1-day lens, the first product explicitly indicated to slow myopia progression in children aged 8 to 12. "Today's approval is the first FDA-approved product to slow the progression of myopia in children, which ultimately could mean a reduced risk of developing other eye problems," stated Malvina Eydelman, M.D., director of the FDA's Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices. Clinical trials demonstrated that these dual-focus lenses slowed refractive progression by 59% and axial elongation by 52% over three years.[2]

Because the raw efficacy ceilings of all three treatments cluster around that 50% to 60% reduction mark, the medical decision rarely hinges on which option is theoretically strongest. Instead, pediatric optometrists emphasize that the most effective treatment is the one a specific family can consistently execute. The locus of compliance shifts dramatically between the options: from the parent administering drops, to the child managing daytime lenses, to the strict hygiene required for overnight corneal molding.[6]

Safety profiles also dictate the choice. Ortho-K carries a well-documented, albeit low, risk of microbial keratitis (corneal infection) due to overnight wear, requiring meticulous cleaning routines. Atropine avoids contact lens risks entirely but can introduce photophobia (light sensitivity) and temporary near-blur, with absolute photophobia rates reaching 9.8% in some atropine cohorts compared to 5.9% in placebo groups. Daily disposable soft lenses sidestep overnight risks and cleaning solutions entirely, presenting an infection rate comparable to adult daily wearers.[2][3][5]

The financial and logistical burdens are equally distinct. Ortho-K requires frequent initial clinic visits to map and fit the rigid lenses, alongside a higher upfront cost. Atropine drops must often be sourced from compounding pharmacies, as specific low-dose formulations are not universally commercialized. Soft multifocals require an ongoing monthly subscription model for the lenses themselves.[6]

For a seven-year-old whose prescription is changing by more than 0.50 diopters annually, the window to act is immediate. The younger the child is when myopia begins, the faster it typically progresses, and the higher the ultimate risk profile becomes. Selecting a management strategy is less about finding a flawless cure and more about matching the intervention's demands to the child's maturity and the family's daily routine.[6]